Cartalax
Anecdotal · 3 studies cited · 2 min · Updated 2026-08-14
In short: Cartalax is the synthetic tripeptide Ala-Glu-Asp, marketed as a "cartilage bioregulator." Unlike Sigumir it has indexed papers — but they are institute-affiliated cell-culture studies in skin fibroblasts and stem cells, not cartilage, and there is zero human data for any indication. The cartilage label is a marketing extrapolation.
Cartalax is the Khavinson-program synthetic tripeptide Ala-Glu-Asp (AED), often sold as the synthetic sibling of Sigumir — where Sigumir is an animal-tissue extract of undisclosed composition, Cartalax is at least a defined molecule. The claimed mechanism is peptide regulation of gene expression in aging connective-tissue cells. The claim has some indexed support — just not in the tissue the product is named after.
What the cell studies show
In aging human mesenchymal stem cell cultures, AED increased IGF1 expression several-fold and shifted aging-related gene expression. In aging skin fibroblasts, it reduced MMP-9 synthesis, increased proliferation markers, and suppressed apoptosis. Taken at face value, that is a real biological signal: a tripeptide shifting the behavior of aging connective-tissue cells in culture. But note what is missing: any demonstration in chondrocytes or cartilage tissue with functional matrix endpoints. Both studies are expression-level results — changes in which genes are switched on, not in what tissue is actually built — without tissue-level or organism-level confirmation, and every indexed AED paper shares authorship with the Khavinson institute. There is no independent replication.
The human evidence
None. There are no indexed human trials of Cartalax or AED for any indication, joint or otherwise, and no registered trial exists as of August 2026. Institute reviews assert clinical utility in osteoarthritis alongside Sigumir, but the primary human studies behind those assertions are not retrievable in PubMed. Vendor sites cite institute monographs and conference abstracts that cannot be verified — material that does not qualify as evidence here.
The "cartilage bioregulator" label
The cell types actually studied — skin fibroblasts and undifferentiated MSCs — are not cartilage. Calling AED a cartilage bioregulator is a marketing extrapolation from adjacent tissue biology, and the 2023 institute review claiming OA animal-model efficacy cites primary papers that are not independently indexed: the same vendor-literature problem that runs through this whole product family.
Regulatory status and safety
Cartalax has no FDA status of any kind; it is sold as a supplement (commonly 10–20 mg capsules in 30-day "courses") with regeneration claims that no indexed trial supports. No pharmacokinetics have been published — whether an orally ingested tripeptide survives digestion to act on joint tissue is undemonstrated. There are no published human safety data; a synthetic tripeptide taken orally is probably low-risk by inference, but that is inference, not data. This entry is research appraisal, not dosing guidance.
What would change the picture
Two studies would move this entry, and both are conspicuously absent: a chondrocyte or cartilage-explant study of AED with matrix-synthesis endpoints, and any registered human trial for any indication. Until then, the honest description is: an interesting gene-expression peptide from a single research network, sold under a tissue name it has never been tested in.
Why this tier? The tripeptide AED does appear in a handful of indexed in-vitro papers, but they are institute-affiliated, use skin fibroblasts and stem-cell gene expression rather than cartilage cells or matrix function, and there are no human trials of any kind. For any joint claim, anecdotal is the ceiling.